MCID: MLG142
MIFTS: 37

Malignant Conjunctival Melanoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Malignant Conjunctival Melanoma

MalaCards integrated aliases for Malignant Conjunctival Melanoma:

Name: Malignant Conjunctival Melanoma 12 15
Conjunctival Melanoma 12 20 17
Malignant Melanoma of Conjunctiva 12 71

Classifications:



External Ids:

Disease Ontology 12 DOID:1751
NCIt 50 C4550
SNOMED-CT 67 255004001
UMLS 71 C0346360

Summaries for Malignant Conjunctival Melanoma

MalaCards based summary : Malignant Conjunctival Melanoma, also known as conjunctival melanoma, is related to conjunctival pigmentation and ocular melanoma. An important gene associated with Malignant Conjunctival Melanoma is MIR518A1 (MicroRNA 518a-1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Development Angiotensin activation of ERK. The drugs Melphalan and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and eye.

Related Diseases for Malignant Conjunctival Melanoma

Diseases related to Malignant Conjunctival Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Related Disease Score Top Affiliating Genes
1 conjunctival pigmentation 30.6 MLANA IFNA2
2 ocular melanoma 30.5 NRAS GNAQ GNA11
3 ocular cancer 30.1 MLANA GNAQ GNA11
4 mucosal melanoma 30.1 NRAS IFNA2 GNAQ GNA11
5 conjunctival nevus 29.8 NRAS MLANA HRAS GNAQ
6 skin melanoma 29.8 NRAS MLANA IFNA2 HRAS GNAQ GNA11
7 nasal cavity cancer 29.6 MLANA HRAS
8 melanoma, uveal 29.6 NRAS MLANA MIR501 HRAS GNAQ GNA11
9 nodular malignant melanoma 29.5 NRAS MLANA HRAS GNAQ GNA11
10 melanoma 29.5 NRAS MLANA MIR302D IFNA2 HRAS GNAQ
11 spitzoid melanoma 29.3 NRAS MLANA HRAS GNAQ GNA11
12 ovarian melanoma 10.3 NRAS MLANA
13 rare tumor 10.3
14 sensory organ benign neoplasm 10.3 NRAS MLANA
15 phakomatosis cesioflammea 10.3 GNAQ GNA11
16 epithelioid cell melanoma 10.3 MLANA GNA11
17 hypocalciuric hypercalcemia, familial, type ii 10.2 GNAQ GNA11
18 melanomatosis 10.2 NRAS MLANA GNAQ
19 weber syndrome 10.1 GNAQ GNA11
20 meningeal melanocytoma 10.1 MLANA GNAQ GNA11
21 hypomelanosis of ito 10.1 NRAS GNAQ GNA11
22 mongolian spot 10.1 MLANA GNAQ GNA11
23 limbal stem cell deficiency 10.1
24 acneiform dermatitis 10.1 NRAS HRAS
25 lentigines 10.1
26 xeroderma pigmentosum, variant type 10.1
27 severe combined immunodeficiency 10.1
28 core binding factor acute myeloid leukemia 10.0 NRAS HRAS
29 meningeal melanoma 10.0 NRAS MLANA GNAQ GNA11
30 oculoectodermal syndrome 10.0 NRAS HRAS
31 malignant leptomeningeal tumor 10.0 NRAS MLANA GNAQ GNA11
32 large intestine adenocarcinoma 10.0 NRAS HRAS
33 nasal cavity adenocarcinoma 10.0 MLANA HRAS
34 melanocytic nevus syndrome, congenital 10.0 NRAS HRAS
35 orbit rhabdomyosarcoma 10.0 NRAS MLANA IFNA2 GNAQ
36 retinal detachment 10.0
37 retinoblastoma 10.0
38 ptosis 10.0
39 conjunctival squamous cell carcinoma 10.0
40 neurofibromatosis 10.0
41 keratoconjunctivitis 10.0
42 lentigo maligna melanoma 10.0
43 squamous cell carcinoma 10.0
44 amelanotic melanoma 10.0
45 benign struma ovarii 10.0 NRAS HRAS
46 nevus, epidermal 9.9 NRAS HRAS GNAQ
47 vulvar disease 9.9 NRAS HRAS
48 differentiated thyroid carcinoma 9.9 NRAS HRAS EIF1AX
49 thyroid gland follicular carcinoma 9.8 NRAS HRAS EIF1AX
50 malignant anus melanoma 9.8 NRAS MLANA HRAS GNA11

Graphical network of the top 20 diseases related to Malignant Conjunctival Melanoma:



Diseases related to Malignant Conjunctival Melanoma

Symptoms & Phenotypes for Malignant Conjunctival Melanoma

Drugs & Therapeutics for Malignant Conjunctival Melanoma

Drugs for Malignant Conjunctival Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Melphalan Approved Phase 2 148-82-3 4053 460612
2
Pancrelipase Approved, Investigational Phase 2 53608-75-6
3
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
4
Lenalidomide Approved Phase 2 191732-72-6 216326
5
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
6 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
7 pancreatin Phase 2
8 Immunosuppressive Agents Phase 2
9 Immunologic Factors Phase 2
10 Antirheumatic Agents Phase 2
11 Protein Kinase Inhibitors Phase 2
12 Alkylating Agents Phase 2
13 Angiogenesis Inhibitors Phase 2
14
Sargramostim Approved, Investigational Phase 1 123774-72-1, 83869-56-1
15 Molgramostim Investigational Phase 1 99283-10-0
16 Imatinib Mesylate Phase 1 220127-57-1 123596
17 Vaccines Phase 1
18 Freund's Adjuvant Phase 1
19 Adjuvants, Immunologic Phase 1
20 CPG-oligonucleotide Phase 1
21 Liver Extracts Early Phase 1
22 Cola Early Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
2 A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid™), Oral Sunitinib (Sutent™) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma Terminated NCT00482911 Phase 2 cyclophosphamide;lenalidomide;sunitinib malate
3 Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study) Completed NCT01046487 Phase 1 Imatinib mesylate, Cyclophosphamide (Dosing level 1 );Imatinib mesylate, Cyclophosphamide (Dosing level 2);Imatinib mesylate, Cyclophosphamide (Dosing level 3)
4 A Multipeptide Vaccine in Melanoma Patients With Evaluation of the Injection Site Microenvironment Completed NCT00705640 Phase 1
5 Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma Completed NCT00471471 Phase 1
6 Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer Terminated NCT00499733 Early Phase 1 cyclophosphamide

Search NIH Clinical Center for Malignant Conjunctival Melanoma

Genetic Tests for Malignant Conjunctival Melanoma

Anatomical Context for Malignant Conjunctival Melanoma

MalaCards organs/tissues related to Malignant Conjunctival Melanoma:

40
Lymph Node, Liver, Eye, Skin, Breast, Testis

Publications for Malignant Conjunctival Melanoma

Articles related to Malignant Conjunctival Melanoma:

(show top 50) (show all 509)
# Title Authors PMID Year
1
Conjunctival and uveal melanoma: Survival and risk factors following orbital exenteration. 61
33573425 2021
2
m6A RNA hypermethylation-induced BACE2 boosts intracellular calcium release and accelerates tumorigenesis of ocular melanoma. 61
33601055 2021
3
Giant conjunctival melanoma in a paranoid schizophrenic man: A case report. 61
33552501 2021
4
Indocyanine Green Angiographic Assessment of Conjunctival Melanocytic Disorders. 61
33591034 2021
5
Management of conjunctival melanoma with local excision and adjuvant brachytherapy. 61
32332870 2021
6
Orbital exenteration for conjunctival melanoma: comparison of long-term outcome between individualised and conventional techniques. 61
33608640 2021
7
Secondary orbital exenteration for conjunctival melanoma: A study of 25 cases. 61
33573797 2021
8
Conjunctival Melanoma Treated With Complete Circumferential Peripheral and Deep Margin Assessment ("Slow Mohs") Surgery. 61
31851016 2021
9
Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma. 61
32618825 2021
10
Conjunctival melanoma: A 20-year survey in a comprehensive medical center. 61
32417175 2021
11
In-vivo imaging for assessing tumor growth in mouse models of ocular melanoma. 61
33406396 2021
12
Interdisciplinary Surveillance of Ocular Melanomas: Experiences in a German Tertiary Centre. 61
33242884 2021
13
Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. 61
33279851 2021
14
Efficacy of immune checkpoint inhibitors in different types of melanoma. 61
32663057 2021
15
Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing. 61
33396957 2020
16
F-18 fluorodeoxyglucose positron emission tomography/computed tomography in conjunctival melanoma with recurrence. 61
33380688 2020
17
Genomic and transcriptomic landscape of conjunctival melanoma. 61
33383577 2020
18
Current Management of Conjunctival Melanoma Part 2: Treatment and Future Directions. 61
33389937 2020
19
The molecular profile of mucosal melanoma. 61
33156594 2020
20
Conjunctival Melanoma: Outcomes based on the American Joint Committee on Cancer Clinical Classification (8th Edition) of 425 Patients at a Single Ocular Oncology Center. 61
33306519 2020
21
Conjunctival melanoma: Risk factors for recurrent or new tumor in 540 patients at a single ocular oncology center. 61
33176471 2020
22
PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome. 61
33266349 2020
23
The natural history of conjunctival naevi in children and adolescents. 61
33199866 2020
24
Conjunctival Melanoma with Ipsilateral, Non-Contiguous Eyelid Involvement: A Case Report and Comprehensive Review of the Literature. 61
33123526 2020
25
Current Management of Conjunctival Melanoma Part 1: Clinical Features, Diagnosis and Histopathology. 61
33342197 2020
26
Orbital exenteration and conjunctival melanoma: a 14-year study at the Jules Gonin Eye Hospital. 61
31959885 2020
27
Transcriptional characterization of conjunctival melanoma identifies the cellular tumor microenvironment and prognostic gene signatures. 61
33046735 2020
28
Conjunctival melanoma: Opportune detection and resolution of a fast-growing conjunctival lesion. 61
32620413 2020
29
Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study. 61
32892167 2020
30
Conjunctival Melanoma: Features and Outcomes Based on the Fitzpatrick Skin Type in 540 Patients at a Single Ocular Oncology Center. 61
32134771 2020
31
Clinical treatment options for early-stage and advanced conjunctival melanoma. 61
32980421 2020
32
Anterior Segment OCTA of Melanocytic Lesions of the Conjunctiva and Iris. 61
32926848 2020
33
First case of melanoma-associated retinopathy with conjunctival melanoma. 61
32093922 2020
34
Conjunctival Melanoma Angiotropic Microsatellitosis: A Mechanism of Local Extravascular Migratory Metastasis. 61
33005619 2020
35
Mascara deposits in an anophthalmic socket mimicking a conjunctival melanoma. 61
32811658 2020
36
Lacrimal drainage apparatus melanoma remotely following treatment and resolution of conjunctival melanoma. 61
32811269 2020
37
Invasive conjunctival melanoma mimicking ocular surface squamous neoplasia: a case series. 61
32675060 2020
38
Extensive conjunctival melanoma successfully treated with surgical resection and pre- and postoperative topical mitomycin C. 61
32674607 2020
39
Conjunctival Melanoma: Outcomes Based on Age at Presentation in 629 Patients at a Single Ocular Oncology Center. 61
32740010 2020
40
Molecular biology in conjunctival melanoma and the relationship to mucosal melanoma. 61
32749776 2020
41
Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. 61
32718045 2020
42
[Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors]. 61
31938823 2020
43
Conjunctival Melanoma: Current Treatments and Future Options. 61
31965542 2020
44
Image Analysis of 3D Conjunctival Melanoma Cell Cultures Following Electrochemotherapy. 61
32545782 2020
45
Controlling Conjunctival Melanoma-To Infinity and Beyond. 61
32215607 2020
46
Incidence and Survival of Patients With Conjunctival Melanoma in Europe. 61
32215588 2020
47
Conjunctival melanoma in an African American man. 61
32140618 2020
48
Intradural Extramedullary Metastatic Conjunctival Malignant Melanoma. 61
32217182 2020
49
Primary Conjunctival Pigmented Basal Cell Carcinoma with Increased Numbers of Intra-Tumour Melanocytes, Mimicking Melanoma: A Case Report and Review of the Literature. 61
32509761 2020
50
Delayed Onset Scleromalacia and Conjunctival Bleb Formation Following Intraoperative Mitomycin C Application during Conjunctival Melanoma Excision. 61
32384819 2020

Variations for Malignant Conjunctival Melanoma

Expression for Malignant Conjunctival Melanoma

Search GEO for disease gene expression data for Malignant Conjunctival Melanoma.

Pathways for Malignant Conjunctival Melanoma

Pathways related to Malignant Conjunctival Melanoma according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 NRAS IFNA2 HRAS GNAQ GNA11
2
Show member pathways
12.65 NRAS HRAS GNAQ GNA11
3
Show member pathways
12.65 NRAS IFNA2 HRAS GNAQ GNA11
4 12.53 NRAS IFNA2 HRAS GNAQ GNA11
5
Show member pathways
12.51 NRAS HRAS GNAQ GNA11
6
Show member pathways
12.4 NRAS HRAS GNAQ GNA11
7
Show member pathways
12.19 NRAS HRAS GNAQ GNA11
8 11.92 NRAS HRAS GNAQ
9
Show member pathways
11.85 HRAS GNAQ GNA11
10
Show member pathways
11.83 HRAS GNAQ GNA11
11 11.82 NRAS HRAS GNAQ
12 11.79 NRAS HRAS GNAQ
13 11.77 NRAS HRAS GNAQ
14
Show member pathways
11.74 NRAS HRAS GNAQ
15
Show member pathways
11.73 NRAS HRAS GNAQ GNA11
16 11.49 NRAS HRAS GNAQ GNA11
17 11.4 NRAS HRAS GNAQ GNA11
18 11.36 HRAS GNAQ GNA11
19 11.06 NRAS HRAS GNAQ GNA11
20
Show member pathways
11.04 NRAS HRAS
21 10.98 NRAS HRAS
22 10.96 NRAS HRAS
23
Show member pathways
10.75 GNAQ GNA11
24 10.73 NRAS HRAS GNAQ
25 10.7 NRAS HRAS GNAQ GNA11
26 10.59 NRAS HRAS

GO Terms for Malignant Conjunctival Melanoma

Biological processes related to Malignant Conjunctival Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 action potential GO:0001508 9.26 GNA11 GNAQ
2 G protein-coupled acetylcholine receptor signaling pathway GO:0007213 9.16 GNAQ GNA11
3 phototransduction, visible light GO:0007603 8.96 GNAQ GNA11
4 entrainment of circadian clock GO:0009649 8.62 GNAQ GNA11

Molecular functions related to Malignant Conjunctival Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTP binding GO:0005525 9.62 NRAS HRAS GNAQ GNA11
2 G-protein beta/gamma-subunit complex binding GO:0031683 9.26 GNAQ GNA11
3 GTPase activity GO:0003924 9.26 NRAS HRAS GNAQ GNA11
4 guanyl nucleotide binding GO:0019001 9.16 GNAQ GNA11
5 type 2A serotonin receptor binding GO:0031826 8.62 GNAQ GNA11

Sources for Malignant Conjunctival Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....